Olvimulogene nanivacirepvec is under clinical development by Genelux and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Olvimulogene nanivacirepvec’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Olvimulogene nanivacirepvec Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Olvimulogene nanivacirepvec overview

Olvimulogene nanivacirepvec (GL-ONC1) is under development for the treatment of advanced peritoneal carcinomatosis, endometrial cancer, ovarian cancer, advanced solid tumor, head and neck cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, melanoma, malignant pleural mesothelioma, fallopian tube cancer, hepatocellular carcinoma and malignant pleural effusion. The therapeutic candidate is administered through intravenous, intrapleural and intraperitoneal  infusion. GL-ONC1 is based on vaccinia virus which is genetically stable oncolytic virus lister strain designed to locate, enter, colonize and destroy cancer cells without harming healthy tissues or organs.

It was also under development for the treatment of acute myeloid leukemia.

Genelux overview

Genelux is a clinical stage biopharmaceutical company. It develops proprietary oncolytic virus based drugs and technologies. The company develops pipeline of products with applications for cancer detection and therapy. It conducts research and development activities in the field of oncolytic virotherapy. Genelux’s pipeline products include GL-ONC1, GL-ONC2, GL-ONC3, GL-ONC4, GL-CTC1, GL-IMG2 and V-VET-1. The company provides platform and imaging technologies such as targeted viruses armed for cancer therapy and companion diagnosis, customized viral vectors, highly specific deep tissue imaging, and veterinary oncology applications. It operates in San Diego and Redlands. Genelux is headquartered in San Diego, California, the US.

Quick View Olvimulogene nanivacirepvec LOA Data

Report Segments
  • Innovator
Drug Name
  • Olvimulogene nanivacirepvec
Administration Pathway
  • Intraperitoneal
  • Intrapleural
  • Intravenous
Therapeutic Areas
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.